NecstGen is proud to announce a new partnership with the WMDA. This collaboration unites two mission-driven organizations with a shared commitment to advancing life-saving cell and gene therapies. Both NecstGen and WMDA operate as non-profit entities, focusing on patient impact and aligning our values with putting patients and donors first.

“Cellular therapy starts with high-quality cells from donors who are protected,” says Lydia Foeken-van Goozen, CEO of WMDA. “We believe that our collaboration with NecstGen will benefit both patients and donors.”

Designed to enable the next generation of cell and gene therapies, the partnership will leverage the strengths of each organisation. NecstGen brings expertise in advanced therapy development and GMP manufacturing, while WMDA contributes its global network and deep experience in donor recruitment and care. By combining these capabilities, we aim to accelerate innovation in cell & gene therapy and improve patient access to new treatments while upholding the highest standards of quality and safety.

“We are excited about the road ahead and will share further updates as our joint effort progresses,” says Tristan Pritchard-Meaker, Head of BD at NecstGen.

As fellow mission-driven teams, NecstGen and WMDA share a vision of collaboration. Our teams will work closely to exchange knowledge, support each other’s initiatives, and address challenges across the cell therapy pipeline – from donor availability to manufacturing scale-up. We will focus on practical steps that make advanced therapies more accessible and sustainable.